MOA Life Plus Co. Ltd. (KOSDAQ: 142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,200.00
-2.00 (-0.17%)
Dec 20, 2024, 12:33 PM KST
-42.03%
Market Cap 44.83B
Revenue (ttm) 17.08B
Net Income (ttm) 6.67B
Shares Out 37.73M
EPS (ttm) 194.56
PE Ratio 6.72
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,246
Open 1,202.00
Previous Close 1,202.00
Day's Range 1,176.00 - 1,229.00
52-Week Range 1,001.00 - 4,500.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 51
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.